DrugPatentWatch Database Updates: New Patent Delistings
✉ Email this page to a colleague
DrugPatentWatch Database Updates: New Patent Delistings
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp Ltd | ADVAIR HFA | fluticasone propionate; salmeterol xinafoate | AEROSOL, METERED | 021254 | Jun 8, 2006 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||
| Glaxo Grp Ltd | ADVAIR HFA | fluticasone propionate; salmeterol xinafoate | AEROSOL, METERED | 021254 | Jun 8, 2006 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET | 209195 | Jul 18, 2017 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-2039 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET | 209195 | Jul 18, 2017 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-2040 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| Horizon | DUEXIS | famotidine; ibuprofen | TABLET | 022519 | Apr 23, 2011 | DISCN | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION | 201739 | Nov 17, 2017 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION | 201739 | Aug 10, 2012 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
